ClinicalTrials.gg
CompletedNCT00309751Updated Feb 23, 2010Results posted

Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

A Phase 3 interventional study of Pitavastatin and Atorvastatin in Type II Diabetes Mellitus and Dyslipidemia, sponsored by Kowa Research Europe. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-02-23.

Sponsored by Kowa Research Europe (part of Kowa Company, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland — 28 open to participants now, 38 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Poland.

Enrollment
196th of 333
418 · median 500
Started
2005
with 9 others
Phase 3
218 of 351
16 open now
Registered
20th of 351
by date

Among the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, this one is the 196th largest by enrollment of the 333 interventional ones that give a count, is one of 10 that started in 2005, is one of 218 in phase 3, and was the 20th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

28 of the 351 studies in Diabetes Mellitus, Type 2 with a site in Poland are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Diabetes Mellitus, Type 2 with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.

03

Conditions studied

  • Type II Diabetes Mellitus
  • Dyslipidemia

Keywords

  • Kowa
  • Type II Diabetes Mellitus
  • Combined Dyslipidemia
  • pitavastatin
  • NK-104
  • Atorvastatin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females (ages 18-75 years)
  • Type II DM treated with oral anti-diabetic medication (sulfonylurea, metformin, glitazones, or combination therapy)
  • Must have been following a restrictive diet
  • Diagnosis of combined dyslipidemia

Exclusion criteria

Exclusion Criteria:

  • Homozygous familial hypercholesterolemia
  • Conditions which may cause secondary dyslipidemia
  • Uncontrolled diabetes mellitus
  • Abnormal pancreatic, liver, or renal function
  • Abnormal serum creatine kinase (CK) above the pre-specified level
  • Significant heart disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Pitavastatin 4 mg QD

    Pitavastatin 4 mg once daily

    Drug: Pitavastatin

  • Active comparator
    Atorvastatin 20 mg QD

    Atorvastatin 20 mg once daily

    Drug: Atorvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)

    Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C)

    Time frame: 12 weeks

Secondary outcomes

  1. Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target

    Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks

    Time frame: 12 weeks

07

Results

Posted Jan 18, 2010

Participant flow

Participant flow — Overall Study
MilestonePitavastatin 4 mg QDAtorvastatin 20 mg QD
Started279139
Safety population275137
Completed248124
Not completed3115

Outcome measures

PrimaryPercent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)

Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C)

Time frame:
12 weeks
Reported as:
Mean · percent change
Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)
percent changePitavastatin 4 mg QDAtorvastatin 20 mg QD
Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C)-40.78 ± 19.599-43.25 ± 16.378
SecondaryNumber of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target

Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks

Time frame:
12 weeks
Reported as:
Number · Participants
Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target
ParticipantsPitavastatin 4 mg QDAtorvastatin 20 mg QD
Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target212111

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4 mg QD———
Atorvastatin 20 mg QD———
Most frequent serious events
Most frequent serious events
EventPitavastatin 4 mg QDAtorvastatin 20 mg QD
Non-cardiac chest painGeneral disorders0/2751/137
Alcohol poisoningInjury, poisoning and procedural complications0/2751/137
Humerus fractureInjury, poisoning and procedural complications0/2751/137
Intervertebral disc disorderMusculoskeletal and connective tissue disorders0/2751/137
Myocardial infarctionCardiac disorders1/2750/137
Tachycardia paroxysmalCardiac disorders1/2750/137
GastroenteritisInfections and infestations1/2750/137
Blood creatinine increasedInvestigations1/2750/137
Most frequent other events
Most frequent other events
EventPitavastatin 4 mg QDAtorvastatin 20 mg QD
DiarrheaGastrointestinal disorders6/2759/137
NasopharyngitisInfections and infestations12/2759/137
MyalgiaMusculoskeletal and connective tissue disorders11/2750/137
HypertensionVascular disorders0/2754/137

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
<=18 years000
Between 18 and 65 years19193284
>=65 years8444128
Age Continuous
Age Continuous(years)Pitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
Mean59.1 ± 9.2159.8 ± 9.0659.4 ± 9.15
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4 mg QDAtorvastatin 20 mg QDTotal
Female12059179
Male15578233
08

Study locations

35 sites
  • CCBR Aalborg
    Aalborg, Denmark
  • CCBR A/S
    Ballerup, Denmark
  • CCBR Vejle
    Vejle, Denmark
  • Gemeinschaftspraxis am Bahnhof
    Berlin-Spandau, Germany
  • Pharmakologisches Studienzentum Chemnitz
    Chemnitz, Germany
  • Internistische Diabetische Schwerpunktpraxis Dr.
    Frankfurt Am Main, Germany
  • Internistische Gemeinschaftspraxis
    Mainz, Germany
  • Gemeinschaftspraxis Dr. Senftleber, Dr. Kohler
    Messkirch, Germany
  • Bhagwan Mahaveer Jain Heart Centre
    Bangalore, India
  • Sri Ramachandra Medical College Hospital
    Chennai, India
  • Apollo Hospitals
    Hyderabaad, India
  • CARE Group of Hospitals
    Hyderabaad, India
  • PD Hinduja Hospital
    Mumbai, India
  • Andromed Breda
    Breda, Netherlands
  • Andromed Eindhoven
    Eindhoven, Netherlands
  • Andromed Noord
    Groningen, Netherlands
  • Andromed Leiden
    Leiden, Netherlands
  • Andromed Nijmegen
    Nijmegen, Netherlands
  • Andromed Rotterdam
    Rotterdam, Netherlands
  • Andromed Oost
    Velp, Netherlands
  • Andromed Zoetermeer
    Zoetermeer, Netherlands
  • Podlaski Osrodek Kardiologii
    Bialystok, Poland
  • NZOZ GCP Dobra Praktyka Lekaska
    Gruziadz, Poland
  • NZOZ Terapia Optima
    Katowice, Poland
  • NZOZ Esculap, Przychodnia Lekary Rodzinnych
    Losice, Poland
  • NZOZ Centrum, Poradnia Kardiologiczna
    Siedlce, Poland
  • Spec. Gab. Lek. Internistyczno-Kardiologicznly
    Tarnow, Poland
  • Woj.Szp.Spec.Nr 1 im. Prof. J. Gasinskiego
    Tychy, Poland
  • Instytut Zywnosci i Zywienia
    Warszawa, Poland
  • Lecznica PROSEN SMO
    Warszawa, Poland
  • Szpital Wolski,im. Dr A. Gostynskiej
    Warszawa, Poland
  • Synexus Reading Clinical Research Centre
    Berkshire, United Kingdom
  • Synexus Lancashire Clinical Research Centre
    Lancashire, United Kingdom
  • Synexus Merseyside Clinical Research Centre
    Liverpool, United Kingdom
  • Synexus Manchester Clinical Research Centre
    Manchester, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2010, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2005
First posted
Apr 3, 2006
Start
Dec 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results first posted
Jan 18, 2010
Last update
Feb 23, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00309751
First posted
Apr 3, 2006
Start date
Dec 2005
Primary completion
Jun 2007
Completion
Jun 2007
Results posted
Jan 18, 2010
Last update
Feb 23, 2010

Study contacts

Dragos Budinski, Med Dr.
study director · Kowa Research Europe

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion